Korean Circulation Journal最新文献_第2页

DFR Shows Promise-But Can It Replace FFR? DFR有希望——但它能取代FFR吗？

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-07-01 Epub Date: 2025-05-08 DOI: 10.4070/kcj.2025.0127

Doyeon Hwang

引用次数: 0

Revisiting the Prognostic Landscape of Hypertrophic Cardiomyopathy and Hypertension: The Critical Role of Left Ventricular Global Longitudinal Strain. 重访肥厚性心肌病和高血压的预后：左心室整体纵向应变的关键作用。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-07-01 DOI: 10.4070/kcj.2025.0214

So-Ree Kim, Mi-Na Kim

引用次数: 0

Evaluation of Exercise Capacity in Fontan Patients and Effects of Pulmonary Vasodilators. Fontan患者运动能力评价及肺血管扩张剂的作用。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-19 DOI: 10.4070/kcj.2025.0163

Sung Hye Kim

引用次数: 0

Pregnancy in Women With Fontan Circulation: Strategic Management for a High-Risk. Fontan循环妇女妊娠：高危策略管理。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-04 DOI: 10.4070/kcj.2025.0176

Soo-Jin Kim

引用次数: 0

When Compatibility Creates Inequality: Blood Type O and the Korean Heart Transplant System. 当相容性造成不平等：O型血和韩国心脏移植系统。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 DOI: 10.4070/kcj.2025.0125

Soo Yong Lee

引用次数: 0

Osfit™, a Novel Stent Designed for the Treatment of Coronary Ostial Lesions: Initial Clinical Experience and Intravascular Ultrasound Evaluation. 用于治疗冠状动脉口病变的新型支架Osfit™：初步临床经验和血管内超声评估

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-02-03 DOI: 10.4070/kcj.2024.0256

Kyoung-Woo Seo, Seung-Jea Tahk, Hyoung-Mo Yang, Hong-Seok Lim, Myeong-Ho Yoon, So-Yeon Choi

{"title":"Osfit™, a Novel Stent Designed for the Treatment of Coronary Ostial Lesions: Initial Clinical Experience and Intravascular Ultrasound Evaluation.","authors":"Kyoung-Woo Seo, Seung-Jea Tahk, Hyoung-Mo Yang, Hong-Seok Lim, Myeong-Ho Yoon, So-Yeon Choi","doi":"10.4070/kcj.2024.0256","DOIUrl":"10.4070/kcj.2024.0256","url":null,"abstract":"Background and objectives: Stent implantation for coronary ostial lesions is challenging. This study evaluated the feasibility, safety, and immediate procedural results of the Osfit™, innovatively designed sirolimus drug-eluting stent delivery system for the treatment of coronary ostial lesions.Methods: The Osfit™ has a 5 mm long extended balloon proximal to the stent (bare balloon without mounted stent). When inflated at 1.5 atm, only bare balloon inflated and acts like a stopper. We evaluated the technical feasibility in 49 patients with a coronary ostial lesion (defined as stenosis within 3 mm from the origin of the vessel) who had received the Osfit™. Intravascular ultrasound (IVUS) analysis was done in 11 patients who consented to IVUS examination, and the depth from the proximal edge of the stent to the ostial plane (DSO) was measured.Results: In all 49 lesions, stents were successfully implanted in one single angiographic view without obvious stent protrusion or definite angiographic missing of the ostium. The proportions of aorto-ostial, and bifurcation lesions were 28.6% and 71.4%, respectively. The DSO was 0.2±0.69 mm, and the proximal stent edges were located within 1 mm of the ostial edge in all patients. No adverse events like death, myocardial infarction, target lesion revascularization, target vessel revascularization or stent thrombosis were reported during the in-hospital period or within 30 days.Conclusions: The implantation of the Osfit™ for coronary ostial lesions appears to be an accurate and safe procedure that may reduce multiple angiographic projections and advanced skills.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":"497-508"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exosome-Based Therapy in Cardiovascular Diseases: A New Frontier in Cardiovascular Disease Treatment. 基于外泌体的心血管疾病治疗：心血管疾病治疗的新前沿。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-03-05 DOI: 10.4070/kcj.2025.0022

Cheong-Whan Chae, Gun Choi, Taehun Yoon, Yoo-Wook Kwon

{"title":"Exosome-Based Therapy in Cardiovascular Diseases: A New Frontier in Cardiovascular Disease Treatment.","authors":"Cheong-Whan Chae, Gun Choi, Taehun Yoon, Yoo-Wook Kwon","doi":"10.4070/kcj.2025.0022","DOIUrl":"10.4070/kcj.2025.0022","url":null,"abstract":"Exosomes, small extracellular vesicles ranging from 30 to 150 nanometers in diameter, have emerged as pivotal mediators of intercellular communication. These vesicles, originally perceived as cellular debris, are now recognized for their intricate roles in transporting bioactive molecules, including proteins, lipids, and nucleic acids, between cells. Exosomes have received considerable attention due to their roles in diverse physiological and pathological processes, especially in relation to cardiovascular diseases (CVDs). CVDs are intricately linked, sharing common risk factors and pathological mechanisms, such as inflammation, oxidative stress, and endothelial dysfunction. Exosomes have been implicated in either directly or indirectly influencing these phenomena. They are secreted by virtually all cell types, including endothelial cells, cardiomyocytes, and stem cells, play critical roles in maintaining vascular homeostasis and responding to pathological stimuli. Their capacity to traverse biological barriers, maintain stability in circulation, and effectively encapsulate and deliver a variety of molecular cargos makes them promising candidates for both biomarkers and therapeutic agents. This review aims to explore the multifaceted roles of exosomes in CVDs. And we will discuss the mechanisms of exosome biogenesis and release, their molecular composition, and the ways in which they contribute to disease pathophysiology. Additionally, we will emphasize the potential of exosomes as diagnostic biomarkers and their therapeutic uses, highlighting their significance in the advancement of innovative treatment strategies. This review explores recent findings and advancements in exosome research, emphasizing their significance in CVD and paving the way for future studies and clinical applications.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":"461-480"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultimately, the Problem Lies in the Arterial Diameter. 最终，问题出在动脉直径上。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-02-19 DOI: 10.4070/kcj.2025.0030

Hyoung Woo Chang

引用次数: 0

Sex Differences in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation. 心源性休克患者接受静脉体外膜氧合的性别差异。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-02-10 DOI: 10.4070/kcj.2024.0330

Onyou Kim, David Hong, Ki Hong Choi, Joo Myung Lee, Taek Kyu Park, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Yang Hyun Cho, Hyeon-Cheol Gwon, Jeong Hoon Yang

{"title":"Sex Differences in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation.","authors":"Onyou Kim, David Hong, Ki Hong Choi, Joo Myung Lee, Taek Kyu Park, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Yang Hyun Cho, Hyeon-Cheol Gwon, Jeong Hoon Yang","doi":"10.4070/kcj.2024.0330","DOIUrl":"10.4070/kcj.2024.0330","url":null,"abstract":"Background and objectives: Limited data are available on sex differences in clinical outcomes of patients with profound cardiogenic shock (CS) receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO). Therefore, our study sought to compare clinical pictures and outcomes between male and female patients treated with VA-ECMO.Methods: A total of 1,328 patients receiving VA-ECMO were selected from either the Samsung Medical Center or a multicenter CS registry named the SMART RESCUE study. The study population was divided into men (n=903) and women (n=425). The primary outcome was in-hospital mortality, and the secondary outcome was procedure-related complications, which included limb ischemia, extracorporeal membrane oxygenation (ECMO) site bleeding and infection, and wound dehiscence.Results: There was no significant difference in in-hospital mortality (men vs. women, 46.4% vs. 45.6%; adjusted odds ratio [OR], 0.78; 95% confidence interval [CI], 0.58-1.05; p=0.106) based on multivariable analysis. Women showed higher rates of procedure-related complication than men (18.7% vs. 25.9%; adjusted OR, 1.82; 95% CI, 1.29-2.57; p=0.001) mainly driven by higher incidence of limb ischemia (7.1% vs. 12.9%; adjusted OR, 2.32; 95% CI, 1.42-3.78; p=0.001) On multivariable logistic regression analysis, female sex was an independent predictor of procedure-related complications (adjusted OR, 1.68; 95% CI, 1.13-2.49; p=0.009).Conclusions: Although no significant difference in either in-hospital or mid-term mortality was found between men and women, female sex is an independent factor for ECMO-related complications.Trial registration: ClinicalTrials.gov Identifier: NCT02985008.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":"541-551"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disparities in Heart Transplantation Allocation and Outcomes by Blood Type in Korea (2010-2022). 韩国心脏移植分配和结果的血型差异（2010-2022）。

IF 3 3区医学

Korean Circulation Journal Pub Date : 2025-06-01 Epub Date: 2025-03-28 DOI: 10.4070/kcj.2024.0281

Kyung-Hee Kim, Byoung Geol Choi, Jin-Oh Choi, In-Cheol Kim, Jong-Chan Youn, Yang Hyun Cho, Hae-Young Lee, Sung-Ho Jung, Byung-Hee Oh

{"title":"Disparities in Heart Transplantation Allocation and Outcomes by Blood Type in Korea (2010-2022).","authors":"Kyung-Hee Kim, Byoung Geol Choi, Jin-Oh Choi, In-Cheol Kim, Jong-Chan Youn, Yang Hyun Cho, Hae-Young Lee, Sung-Ho Jung, Byung-Hee Oh","doi":"10.4070/kcj.2024.0281","DOIUrl":"10.4070/kcj.2024.0281","url":null,"abstract":"Background and objectives: This study aimed to elucidate the influence of recipient blood type on heart transplant allocation dynamics in Korea, focusing on donor matching, wait times, and post-transplant survival from 2010 to 2022.Methods: In this retrospective cohort study, we examined 1,745 heart transplant recipients classified by blood types: A (n=631), B (n=488), AB (n=256), and O (n=370). Parameters studied encompassed donor and recipient ages, donor blood type compatibility, organ type, emergency status, waiting periods, and survival rates up to one year post-transplant.Results: This investigation revealed significant disparities in the outcomes for heart transplant waitlist patients, differentiated by blood type. O recipients encountered notably extended median wait times of 110 days (an average of 300±514 days), which is substantially longer compared to A (65 days), B (58 days), and AB (29 days). Furthermore, the mortality rate for O recipients while on the waitlist was markedly high at 78.1%, in contrast to 75.2% for A, 72.3% for B, and 48.5% for AB. O recipients who, despite constituting a significant proportion of the donor pool (34.1%), received transplants at disproportionately lower rates.Conclusions: Type O heart transplant recipients in Korea face significant challenges, including higher mortality rates during the waiting period and frequent necessity for left ventricular assist device interventions. Urgent policy reforms are needed to address these disparities and improve equitable organ allocation for blood type O patients.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":"481-493"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12206615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0